RBC Capital Reiterates Outperform Rating on Arrowhead Pharma (ARWR)
Tweet Send to a Friend
RBC Capital analyst Luca Issi reiterated an Outperform rating and $50.00 price target on Arrowhead Pharma (NASDAQ: ARWR)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


